Sublicense Income. Subject to Section 5.6(f), the Opt-In Party will pay to Regulus a portion of the Sublicense Income received by the Opt-In Party or its Affiliates, in accordance with the following table: Prior to Completion of first Phase IIa Clinical Trial [***] % After Completion of first Phase IIa Clinical Trial, but prior to completion of first Phase III Clinical Trial [***] % After Completion of first Phase III Clinical Trial [***] %
Appears in 2 contracts
Samples: License and Collaboration Agreement (Alnylam Pharmaceuticals, Inc.), License and Collaboration Agreement (Isis Pharmaceuticals Inc)
Sublicense Income. Subject to Section 5.6(f), the Opt-In Party will pay to Regulus a portion of the Sublicense Income received by the Opt-In Party or its Affiliates, in accordance with the following table: Prior to Completion of first Phase IIa Clinical Trial [...***] ...]% After Completion of first Phase IIa Clinical Trial, but prior to completion of first Phase III Clinical Trial [...***] ...]% After Completion of first Phase III Clinical Trial [...***] ...]%
Appears in 1 contract
Samples: License and Collaboration Agreement (Regulus Therapeutics Inc.)
Sublicense Income. Subject to Section 5.6(f), the Opt-In Party will pay to Regulus a portion of the Sublicense Income received by the Opt-In Party or its Affiliates, in accordance with the following table: Prior to Completion of first Phase IIa Clinical Trial [...***...] % After Completion of first Phase IIa Clinical Trial, but prior to completion of first Phase III Clinical Trial [...***...] % After Completion of first Phase III Clinical Trial [...***...] %
Appears in 1 contract
Samples: License and Collaboration Agreement (Regulus Therapeutics Inc.)
Sublicense Income. Subject to Section 5.6(f), the Opt-In Party will pay to Regulus a portion of the Sublicense Income received by the Opt-In Party or its Affiliates, in accordance with the following table: Prior to Completion of first Phase IIa Clinical Trial [***] ]% After Completion of first Phase IIa Clinical Trial, but prior to completion of first Phase III Clinical Trial [***] ]% After Completion of first Phase III Clinical Trial [***] ]%
Appears in 1 contract
Samples: License and Collaboration Agreement (Alnylam Pharmaceuticals, Inc.)
Sublicense Income. Subject to Section 5.6(f), the Opt-In Party will pay to Regulus a portion of the Sublicense Income received by the Opt-In Party or its Affiliates, in accordance with the following table: Prior to Completion of first Phase IIa Clinical Trial [***] ]% After Completion of first Phase IIa Clinical Trial, but prior to completion of first Phase III Clinical Trial [***] ]% After Completion of first Phase III Clinical Trial [***] ]%
Appears in 1 contract
Samples: License and Collaboration Agreement (Isis Pharmaceuticals Inc)
